Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.80 USD

96.80
523,757

-0.91 (-0.93%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $96.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks News

Illumina (ILMN) Grows on Innovation & Strategic Partnerships

Illumina's (ILMN) alliances with Bristol-Myers Squibb and Loxo Oncology to reap positive results in oncology.

    Here's Why You Should Invest in Baxter International Now

    Strategic buyouts consistently help Baxter (BAX) gain market traction. Recently, the company completes the consolidation of both RECOTHROM and PREVELEAK.

      ResMed's (RMD) HEALTHCAREfirst Buyout to Boost SaaS Business

      Integration of HEALTHCAREfirst's solutions suite with ResMed's (RMD) SaaS portfolio will help manage the burgeoning population and provide benefits to patients.

        Here's Why You Should Add ResMed (RMD) to Your Portfolio Now

        With a view to consistently lead the SDB market and boost the company's sales, ResMed (RMD) sets sights on product development and innovation.

          Here's Why STERIS (STE) Stock is a Must Buy at the Moment

          STERIS (STE) gains ground on strategic buyouts and divestments.

            Myriad Genetics' Planned Counsyl Buyout to Widen Portfolio

            Myriad Genetics (MYGN) plans to retain Counsyl as a wholly-owned subsidiary post the successful completion of the acquisition.

              IDEXX's (IDXX) Catalyst Uptake Remains Strong & Boosts CAG

              Solid organic growth trend within IDEXX's (IDXX) CAG revenues to sustain on the back of a strong global placement of high-premium Catalyst instruments.

                Abbott Presents Positive Data for AMPLATZER Amulet Device

                Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.

                  Abbott Presents Positive Study Results for Tendyne Device

                  Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.

                    Myriad Genetics' Prolaris Expands on New Coverage Decisions

                    This increased rate in commercial insurer coverage for Myriad Genetics' (MYGN) Prolaris comes close on the heels of the NCCN guidelines.

                      Here's Why You Should Buy Boston Scientific (BSX) Stock Now

                      Boston Scientific's (BSX) inorganic expansion plan bodes well for operational growth.

                        Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing

                        Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.

                          Medtronic (MDT) Q4 Earnings: Can Spine Division Turn Around?

                          Medtronic (MDT) expects to demonstrate positive outcome related to its distribution relationship with Mazor Robotics.

                            Zimmer Biomet New System Gets FDA Nod, to Boost Spine Wing

                            Zimmer Biomet (ZBH) receives FDA's approval for the new system, which is likely to augment the company's lumbar spacers portfolio.

                              Cardiovascular Systems Rides on New Products Amid Tight Race

                              Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.

                                Will Solid Diabetes Arm Drive Medtronic's (MDT) Q4 Earnings?

                                Medtronic (MDT) is poised to gain on strength in Diabetes business in Q4 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.

                                  Here's Why You Should Invest in Illumina (ILMN) Stock Now

                                  Illumina (ILMN) gains ground on product launches and international prospects.

                                    Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?

                                    Medtronic (MDT) is poised to gain on continued strength in RTG business in Q4.

                                      Zacks.com featured highlights include: Louisiana-Pacific, Amedisys, MGM, Oshkosh and Federated National

                                      Zacks.com featured highlights include: Louisiana-Pacific, Amedisys, MGM, Oshkosh and Federated National

                                        Amedisys or Chemed: Which is a Better Investment Choice?

                                        After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).

                                          Buy These 5 Low Leverage Stocks to Strengthen Your Portfolio

                                          With the Q1 earnings season in its last lap, we would recommend investors to avoid high-leveraged stocks, even if they are exhibiting solid earnings growth.

                                            Can Amedisys (AMED) Stock Continue to Grow Earnings?

                                            Amedisys (AMED) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

                                              Amedisys (AMED) Q1 Earnings, Revenues Beat on Overall Growth

                                              Robust growth in Medicare and non-Medicare revenues at Amedisys' (AMED) Home Health and Hospice divisions boost the company's Q1 results.

                                                Healthcare Stocks' Earnings Due on May 7: EVHC, PINC & More

                                                Acute flu, aging population, increase in patient volumes and high claims would affect healthcare companies' Q1 earnings.

                                                  Amedisys (AMED) Up 1.9% Since Earnings Report: Can It Continue?

                                                  Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.